Centre de Recherche Saint-Louis | Clinique Medicale Saint-Louis

Research site

(Unclaimed)

Location

3165 Chemin St-Louis Suite 220, Quebec, Quebec, Canada

Site insights

Top conditions

Top treatments

Metformin

Sugar

Rocatinlimab

PF-06700841

PF-05221304

Ritlecitinib

Tirzepatide

Abrocitinib

PF-06651600

PF-06882961

Parent organization

This site is a part of Centre de Recherche Saint-Louis

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 36 total trials

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo

Enrolling

Stable Nonsegmental Vitiligo

Active Nonsegmental Vitiligo

Drug: Ritlecitinib

Drug: Placebo

Locations recently updated

A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo (Tranquillo LTE)

This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV).Ritlecitinib is studied in patient...

Enrolling

Vitiligo

Drug: Ritlecitinib

Drug: Ritlecitinib 100 mg

A Research Study to See How Much CagriSema (1.0 mg Once Weekly) Lowers Blood Sugar and Body Weight Compared to Tirzepatide (5 mg Once Weekly) in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both (REIMAGINE 5)

This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medi...

Begins enrollment in 1 month

Diabetes Mellitus, Type 2

Drug: Cagrilintide

Drug: Semaglutide

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigatio...

Enrolling

Type 2 Diabetes

Drug: Semaglutide

Drug: Cagrilintide

A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor (REIMAGINE 2)

The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two...

Active, not recruiting

Type 2 Diabetes Mellitus

Drug: Cagrilintide

Drug: Semaglutide

A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-SHUTTLE)

The coprimary objectives of the study are to:* evaluate the efficacy of rocatinlimab in combination with topical corticosteroid and/or topical calcin...

Active, not recruiting

Atopic Dermatitis

Drug: Rocatinlimab

Other: Placebo

A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) (ROCKET-VOYAGER)

The primary objectives of this study are to:* estimate vaccine response in rocatinlimab group vs placebo group, assessed using antibody anti-tetanus...

Active, not recruiting

Atopic Dermatitis

Moderate-to-severe Atopic Dermatitis

Drug: Placebo

Drug: Rocatinlimab

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) (TRuE-PN1)

The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).

Enrolling

Prurigo

Drug: Ruxolitinib Cream

Drug: Vehicle Cream

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic der...

Enrolling

Atopic Dermatitis

Drug: PF-07264660

Drug: PF-07275315

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (JADE EXTEND)

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting

Dermatitis, Atopic

Drug: Abrocitinib 200 mg

Drug: Abrocitinib 100 mg

Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. (RENOIR)

Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a...

Active, not recruiting

Lower Respiratory Tract Illness

Biological: RSVpreF

Biological: Placebo